Announcement • Apr 11
GlaxoSmithKline S.A.E, Annual General Meeting, May 03, 2026 GlaxoSmithKline S.A.E, Annual General Meeting, May 03, 2026, at 15:30 Egypt Standard Time. Location: cairo Egypt Announcement • Dec 31
GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026 GlaxoSmithKline S.A.E announced Annual dividend of EGP 1.0000 per share payable on January 14, 2026, ex-date on January 12, 2026 and record date on January 13, 2026. Reported Earnings • May 15
First quarter 2025 earnings released: EPS: ج.م0.71 (vs ج.م0.11 loss in 1Q 2024) First quarter 2025 results: EPS: ج.م0.71 (up from ج.م0.11 loss in 1Q 2024). Revenue: ج.م993.9m (up 39% from 1Q 2024). Net income: ج.م59.1m (up ج.م68.1m from 1Q 2024). Profit margin: 5.9% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year. Board Change • May 14
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • May 06
GlaxoSmithKline S.A.E, Annual General Meeting, May 28, 2025 GlaxoSmithKline S.A.E, Annual General Meeting, May 28, 2025, at 15:00 Egypt Standard Time. Location: cairo Egypt Reported Earnings • Nov 16
Third quarter 2024 earnings released: EPS: ج.م0.16 (vs ج.م0.33 in 3Q 2023) Third quarter 2024 results: EPS: ج.م0.16 (down from ج.م0.33 in 3Q 2023). Revenue: ج.م787.1m (up 37% from 3Q 2023). Net income: ج.م13.3m (down 51% from 3Q 2023). Profit margin: 1.7% (down from 4.7% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Oct 14
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ج.م45.80, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 104% over the past three years. Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ج.م36.23, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 50% over the past three years. Reported Earnings • Aug 18
Second quarter 2024 earnings released: EPS: ج.م1.22 (vs ج.م0.07 in 2Q 2023) Second quarter 2024 results: EPS: ج.م1.22 (up from ج.م0.07 in 2Q 2023). Revenue: ج.م642.4m (up 19% from 2Q 2023). Net income: ج.م101.5m (up ج.م95.8m from 2Q 2023). Profit margin: 16% (up from 1.1% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 7% per year. Upcoming Dividend • Jul 11
Upcoming dividend of ج.م0.75 per share Eligible shareholders must have bought the stock before 18 July 2024. Payment date: 22 July 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Egyptian dividend payers (7.2%). Lower than average of industry peers (3.1%). Reported Earnings • May 18
First quarter 2024 earnings released First quarter 2024 results: Revenue: ج.م713.8m (up 55% from 1Q 2023). Net loss: ج.م8.99m (down 165% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. New Risk • May 03
New major risk - Revenue and earnings growth Earnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (ج.م2.60b market cap, or US$54.1m). New Risk • Apr 28
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (ج.م2.58b market cap, or US$53.9m). Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ج.م29.32, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 9x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 29% over the past three years. Reported Earnings • Mar 07
Full year 2023 earnings released Full year 2023 results: Revenue: ج.م2.24b (up 23% from FY 2022). Net income: ج.م74.1m (up ج.م205.1m from FY 2022). Profit margin: 3.3% (up from net loss in FY 2022). Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ج.م42.66, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 10x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 40% over the past three years. New Risk • Dec 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م2.95b market cap, or US$95.3m). New Risk • Aug 30
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Market cap is less than US$100m (ج.م2.61b market cap, or US$84.4m). Upcoming Dividend • Jun 27
Upcoming dividend of ج.م0.75 per share at 2.3% yield Eligible shareholders must have bought the stock before 04 July 2023. Payment date: 06 July 2023. Trailing yield: 2.3%. Lower than top quartile of Egyptian dividend payers (7.6%). Lower than average of industry peers (3.6%). Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ج.م37.45, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 376% over the past three years. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ج.م28.01, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 362% over the past three years. Upcoming Dividend • Dec 28
Upcoming dividend of ج.م3.00 per share Eligible shareholders must have bought the stock before 04 January 2023. Payment date: 08 January 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.8%). Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ج.م35.37, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 93% over the past three years. Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improved over the past week After last week's 22% share price gain to ج.م29.39, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 61% over the past three years. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Sep 13
Upcoming dividend of ج.م0.75 per share Eligible shareholders must have bought the stock before 20 September 2022. Payment date: 22 September 2022. Trailing yield: 2.1%. Lower than top quartile of Egyptian dividend payers (10%). Lower than average of industry peers (4.1%). Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Feb 15
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ج.م23.33, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 38% over the past year. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ج.م20.08, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 6.1% over the past three years. Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ج.م23.90, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 44% over the past year. Upcoming Dividend • Jun 28
Upcoming dividend of ج.م0.50 per share Eligible shareholders must have bought the stock before 05 July 2021. Payment date: 07 July 2021. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.2%). Announcement • Mar 12
Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC). Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited on January 25, 2021. The transaction would be subject to satisfaction of certain conditions, including but not limited to (i) the completion of satisfactory due diligence, (ii) the entry into definitive and binding legal documents; and (iii) obtaining the approval(s) of the regulatory authorities. As of January 27, 2021, The board of directors of GlaxoSmithKline S.A.E agreed to allow Hikma Pharmaceuticals Plc to conduct due diligence.
Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC) on March 11, 2021. Announcement • Feb 02
Glaxo Group Receives Letter from ACDIMA for Acquisition of Glaxosmithkline Shares Glaxo Group Limited received letter from Acdima - Arab Co. For Drugs Industries & Medical Appliances expressing interest in positioning an offer for potential acquisition of shares of majority shareholder in GlaxoSmithKline S.A.E (CASE:BIOC). Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment improved over the past week After last week's 29% share price gain to ج.م21.28, the stock is trading at a trailing P/E ratio of 8.2x, up from the previous P/E ratio of 6.4x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total return to shareholders over the past three years is a loss of 9.7%. Is New 90 Day High Low • Jan 27
New 90-day high: ج.م19.35 The company is up 24% from its price of ج.م15.59 on 28 October 2020. The Egyptian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Is New 90 Day High Low • Dec 21
New 90-day low: ج.م15.15 The company is down 1.0% from its price of ج.م15.35 on 22 September 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Reported Earnings • Nov 17
Third quarter 2020 earnings released: ج.م0.17 loss per share The company reported a soft third quarter result with weaker earnings and control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: ج.م483.6m (up 12% from 3Q 2019). Net loss: ج.م14.6m (down 138% from profit in 3Q 2019). Is New 90 Day High Low • Nov 02
New 90-day low: ج.م15.22 The company is down 11% from its price of ج.م17.06 on 04 August 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Is New 90 Day High Low • Oct 04
New 90-day high: ج.م18.34 The company is up 9.0% from its price of ج.م16.82 on 06 July 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period.